Is Cosmo Pharmaceuticals N.V. (COPN.SW) a Buy, Sell, or Hold?
SIX : COPN.SW
Cosmo Pharmaceuticals N.V. — News
$60 CHF
-$0.6 (-0.99%)
- Volume
- 34.58K
- Average Volume
- 36.17K
- Market Capitalization
- $1.03B
- P/E Ratio
- -169.44
- Dividend Yield
- 3.25%
- Price Target
- Year High
- $129.40
- Year Low
- $53.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$6.93
- Current Ratio
- $10.66
| Source | Headline |
|---|---|
|
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR feeds.newsfilecorp.com - 2026-07-23 01:01:00 |
|
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) ("Cosmo") announced feeds.newsfilecorp.com - 2026-07-01 01:00:00 |
|
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) ("Cosmo") is pleased to make known that its feeds.newsfilecorp.com - 2026-06-11 01:19:00 |
|
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) feeds.newsfilecorp.com - 2026-05-18 01:03:00 |
